New guidelines standardize diagnosis and monitoring of canine dementia: full analysis

Veterinarians now have a consensus framework for diagnosing and monitoring canine cognitive dysfunction syndrome, with an international working group publishing what appear to be the first formal guidelines for CCDS in JAVMA. The paper, published online on December 24, 2025, aims to standardize how clinicians identify, stage, and follow dogs with age-related cognitive decline, a condition often referred to as canine dementia. (elib.tiho-hannover.de)

The move comes after years of concern that CCDS has been both underrecognized and inconsistently defined in practice. In the guideline paper, the authors say the lack of consensus standards has contributed to diagnostic inaccuracy, uneven monitoring, and slower research progress. That need was echoed in a 2025 survey of U.S. veterinarians, where 63.8% of respondents said standardized diagnostic criteria or better guidance for distinguishing CCDS from other age-related disease would make them more confident in diagnosis. (elib.tiho-hannover.de)

The working group, led by NC State’s Natasha Olby and including neurologists, behaviorists, primary care veterinarians, and other experts, defines CCDS as a chronic, progressive, age-associated neurodegenerative syndrome marked by cognitive and behavioral changes that affect daily life. The guidance uses the DISHAA framework to organize those changes: disorientation, social interaction, sleep disruption, house soiling, learning and memory, activity changes, and anxiety. It also proposes three severity stages. Mild disease may be easy to miss because signs are subtle and often attributed to normal aging, while moderate and severe disease increasingly interfere with daily function and require management changes or comprehensive support. (news.ncsu.edu)

A key practical change is the introduction of two diagnostic certainty levels. Level 1 relies on a consistent history of progressive DISHAA signs, exclusion of alternative causes through physical, orthopedic, and neurologic examination, and minimum database testing such as CBC, chemistry, and urinalysis. Level 2 adds brain MRI evidence of cortical atrophy and normal CSF cell counts. The paper also recommends annual screening for behavioral signs starting at age 7, then CCDS scale monitoring every six months if abnormalities are reported, and every six months for all dogs beginning at age 10. The authors recommend DISHAA for ease of clinical use, though CADES, CCDR, and the Canine Cognitive Assessment Scale are listed as alternatives. (elib.tiho-hannover.de)

Industry and professional coverage has framed the guidelines as a first for the field. AAHA’s Trends noted that these are the first published guidelines for diagnosis and monitoring of CCDS, and highlighted Olby’s comments about the practical barriers to diagnosis in primary care, including lack of definitive tests, time constraints during appointments, dependence on caregiver-reported behavior, and difficulty distinguishing CCDS from other neurologic or systemic disease. AAHA’s coverage also pointed to an important limitation: promising biomarkers remain investigational, and normal trajectories across breeds and life stages still need to be defined before they’re ready for routine use. (aaha.org)

That limitation is important for clinicians because it reinforces that these guidelines are less about a single new test and more about standardizing a workflow. The 2025 Frontiers survey suggests current approaches remain highly variable: nearly all veterinarians reported relying on history and clinical signs, but only about one-third used a screening questionnaire, and just 1.9% reported using advanced imaging. In other words, the new framework may be most useful not because it changes every diagnostic tool available today, but because it gives general practitioners a more defensible way to separate likely CCDS from normal aging and from treatable differentials. (frontiersin.org)

Why it matters: As dogs live longer, veterinary teams are seeing more age-related cognitive decline, yet subtle early signs can be overshadowed by osteoarthritis, sensory loss, endocrine disease, pain, or intracranial pathology. A standardized framework could improve case recognition, support earlier conversations with pet parents, and create more consistent monitoring over time. It may also help clinical research by giving investigators a shared case definition and staging system, something the authors and NC State both say is necessary if the field is going to develop and assess future therapies more rigorously. (news.ncsu.edu)

What to watch: The next phase will likely focus on validation, especially around blood biomarkers, cognitive testing tools that work in routine practice, and whether primary care clinics adopt the recommended screening cadence for senior dogs. If uptake is strong, these guidelines could become the baseline framework for both geriatric wellness screening and CCDS clinical trials over the next few years. That last point is an inference based on the paper’s stated research goals and the profession’s documented demand for standardization. (elib.tiho-hannover.de)